β-Glucan–conjugated anti–PD-L1 antibody enhances antitumor efficacy in preclinical mouse models

Addition of Immune Checkpoint Inhibitors to Chemotherapy vs Chemotherapy Alone as First-Line Treatment in Extensive-Stage Small-Cell Lung Carcinoma: A Systematic Review and Meta-Analysis

(2022) Edurne Arriola et al.   Oncology and Therapy

Immune Checkpoint Inhibitor Therapy in Oncology

(2022) Sean Tan et al.   JACC: CardioOncology

TLR Agonists as Mediators of Trained Immunity: Mechanistic Insight and Immunotherapeutic Potential to Combat Infection

(2021) Allison M. Owen et al.   Frontiers in Immunology

Antitumor effect of soluble β-glucan as an immune stimulant

(2021) Lijuan Wu et al.   INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES

Regorafenib enhances anti-PD1 immunotherapy efficacy in murine colorectal cancers and their combination prevents tumor regrowth

(2021) Dennis Doleschel et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Anti–PD-1 and Anti–PD-L1 in Head and Neck Cancer: A Network Meta-Analysis

(2021) Andrea Botticelli et al.   Frontiers in Immunology

ImmuCellAI-mouse: a tool for comprehensive prediction of mouse immune cell abundance and immune microenvironment depiction

(2021) Ya-Ru Miao et al.   BIOINFORMATICS

New insights into the anti- hepatoma mechanism of triple-helix β- glucan by metabolomics profiling

(2021) Liqin Cai et al.   CARBOHYDRATE POLYMERS

Immune Modulating Antibody–Drug Conjugate (IM-ADC) for Cancer Immunotherapy

(2021) Lei He et al.   JOURNAL OF MEDICINAL CHEMISTRY

Reprogramming NK cells and macrophages via combined antibody and cytokine therapy primes tumors for elimination by checkpoint blockade

(2021) Chensu Wang et al.   Cell Reports

Chemokines in the Landscape of Cancer Immunotherapy: How They and Their Receptors Can Be Used to Turn Cold Tumors into Hot Ones?

(2021) Nathan Karin   Cancers

The progress and confusion of anti-PD1/PD-L1 immunotherapy for patients with advanced non-small cell lung cancer

(2020) Shuling Zhang et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

The Complexity of Targeting Chemokines to Promote a Tumor Immune Response

(2020) Marianne Strazza et al.   INFLAMMATION

Potential and unsolved problems of anti-PD-1/PD-L1 therapy combined with radiotherapy

(2020) Yiyi Cao et al.   TUMORI

Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity

(2020) Won Suk Lee et al.   EXPERIMENTAL AND MOLECULAR MEDICINE

Enhancing KDM5A and TLR activity improves the response to immune checkpoint blockade

(2020) Liangliang Wang et al.   Science Translational Medicine

Anti-angiogenic Agents in Combination With Immune Checkpoint Inhibitors: A Promising Strategy for Cancer Treatment

(2020) Yuxiao Song et al.   Frontiers in Immunology

Glycoengineering of Antibodies for Modulating Functions

(2019) Lai-Xi Wang et al.   Annual Review of Biochemistry

Bladder cancer, a unique model to understand cancer immunity and develop immunotherapy approaches

(2019) Dongkui Song et al.   JOURNAL OF PATHOLOGY

Beta Glucan: Supplement or Drug? From Laboratory to Clinical Trials

(2019) Vaclav Vetvicka et al.   MOLECULES

Targeting Tumors with IL-10 Prevents Dendritic Cell-Mediated CD8+ T Cell Apoptosis

(2019) Jian Qiao et al.   CANCER CELL

Inhibition of tumor growth by β-glucans through promoting CD4+ T cell immunomodulation and neutrophil-killing in mice

(2019) Siwei Zou et al.   CARBOHYDRATE POLYMERS

A β-1,3/1,6-glucan from Durvillaea Antarctica inhibits tumor progression in vivo as an immune stimulator

(2019) Fan Su et al.   CARBOHYDRATE POLYMERS

The Role of TLRs in Anti-cancer Immunity and Tumor Rejection

(2019) Zuzanna Urban-Wojciuk et al.   Frontiers in Immunology

Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors

(2019) Satya Das et al.   Journal for ImmunoTherapy of Cancer

A β-glucan from Durvillaea Antarctica has immunomodulatory effects on RAW264.7 macrophages via toll-like receptor 4

(2018) Yi Yang et al.   CARBOHYDRATE POLYMERS

Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors

(2018) Kristian M. Hargadon et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Tackling Cancer Resistance by Immunotherapy: Updated Clinical Impact and Safety of PD-1/PD-L1 Inhibitors

(2018) Shifaa Abdin et al.   Cancers

PD-1/PD-L1 immune checkpoint: Potential target for cancer therapy

(2018) Fatemeh K. Dermani et al.   JOURNAL OF CELLULAR PHYSIOLOGY

β-glucans as potential immunoadjuvants: A review on the adjuvanticity, structure-activity relationship and receptor recognition properties

(2018) Yiming Jin et al.   VACCINE

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

(2017) Anthony B El-Khoueiry et al.   LANCET

Dectin 1 activation on macrophages by galectin 9 promotes pancreatic carcinoma and peritumoral immune tolerance

(2017) Donnele Daley et al.   NATURE MEDICINE

PD-L1 and gastric cancer prognosis: A systematic review and meta-analysis

(2017) Lihu Gu et al.   PLoS One

Immune checkpoint inhibitor combinations in solid tumors: opportunities and challenges

(2016) Chrisann Kyi et al.   Immunotherapy

A polysaccharide from Lentinus edodes inhibits human colon cancer cell proliferation and suppresses tumor growth in athymic nude mice

(2016) Jinglin Wang et al.   Oncotarget

The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment

(2015) G. K. Pennock et al.   ONCOLOGIST

Lentinan reduces tumor progression by enhancing gemcitabine chemotherapy in urothelial bladder cancer

(2015) Ming Sun et al.   SURGICAL ONCOLOGY-OXFORD

Checkpoint blockade for cancer therapy: revitalizing a suppressed immune system

(2015) Yago Pico de Coaña et al.   TRENDS IN MOLECULAR MEDICINE

Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer

(2013) M. Sznol et al.   CLINICAL CANCER RESEARCH

Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy

(2013) Omid Hamid et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

(2013) Omid Hamid et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity

(2012) Suzanne L Topalian et al.   CURRENT OPINION IN IMMUNOLOGY

Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

(2011) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma

(2010) Ryosuke Hino et al.   CANCER

The effects of β-glucan on human immune and cancer cells

(2009) Godfrey Chan et al.   Journal of Hematology & Oncology